Axsome Therapeutics: FDA Approves Symbravo for Acute Treatment of Migraine
A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.
5 Drug Classes Linked to Increased Fall Risk Among Adults with COPD Near End of Life
Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial
The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.
Furosemide Fails to Reduce Risk of Dangerous de novo Postpartum Hypertension: New Research
Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.
Tool Predicts Age at Cognitive Impairment, Dementia Onset: Daily Dose
Your daily dose of the clinical news you may have missed.
PTSD Treatment Advancements: Brexpiprazole-Sertraline Offers New Hope in Phase 3 Trial
Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.
Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial
Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.
Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study
The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.
High-Dose Semaglutide Linked to Increased Weight Loss: Daily Dose
FDA Approves New Indication for Semaglutide (Ozempic) to Lower Kidney Risks in Type 2 Diabetes, CKD
This newest approval established Ozempic as the most broadly indicted GLP-1 RA in its class.
Alzheimer Assessment Update: Alzheimer's Association Publishes New Appropriate Use Criteria for Amyloid and Tau PET
Bariatric Surgery Lowers Risk of Liver Complications in Patients with Cirrhosis, Obesity
Metabolic surgery reduced major adverse liver outcomes in people with compensated cirrhosis and obesity by 72%, according to new data.
Neurocrine Biosciences Launches Phase 3 Registration Program for Osavampator in Major Depressive Disorder
The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.
AI Model Identifies Women with Subjective Cognitive Decline During Menopause: Daily Dose
Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD
Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.
CVD Remains Leading Cause of Death in US: AHA 2025 Statistical Update
Cardiovascular disease is still the leading cause of death in the US, driven by rising rates of obesity, diabetes, and hypertension, according to new report.
Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction: Topline Phase 2b Data
In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.
Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis
Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.
Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD
Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.
FDA Approves Mirikizumab for Crohn Disease: Daily Dose
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Fall Risk Near End of Life in COPD / image credit ©Toa555/shutterstock.com")
